Research programme: herpes simplex virus-2 vaccines - NanoBio

Drug Profile

Research programme: herpes simplex virus-2 vaccines - NanoBio

Alternative Names: Nanoemulsion adjuvanted intramuscular HSV-2 vaccine - NanoBio; Nanoemulsion adjuvanted intranasal HSV-2 vaccine - NanoBio; NE glycoprotein vaccine - NanoBio; NE-HSV2

Latest Information Update: 21 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NanoBio Corporation
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Herpes simplex virus type 2 infections

Most Recent Events

  • 06 Mar 2017 Research programme: herpes simplex virus-2 vaccines is still in preclinical development for Herpes simplex virus type-2 infections (prevention and treatment) (Intranasal, IM) in USA
  • 06 Mar 2017 NanoBio Corporation receives a phase II SBIR grant from National Institute of Allergy and Infectious Diseases (NIAID) for Herpes simplex virus-2 infection (Prevention) (Intranasal)
  • 28 Sep 2015 Pharmacodynamics and adverse events data from preclinical trials in Herpes simplex virus type-2 infection released by NanoBio
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top